CD274 and neoplasm: IL-6 activates the NF-κB (nuclear factor “kappa-light-chain-enhancer” of activated B-cells) pathway, which makes the cells less sensitive to attenuation of EGFR tyrosine kinase inhibitors [64] and induces the upregulation of programmed death-ligand (PD-L1) on peripheral myeloid cells, which promotes tumor growth in orthotopic mice models [65].